Want to see CGEM full AI Analyst Report?

Cullinan Management (CGEM) Price & Analysis

357 Followers

CGEM Stock Chart & Stats

$15.06

-$0.28(-2.38%)

At close: Jan 08 4:00 PM EST

$15.06

-$0.28(-2.38%)

Day’s Range― - ―

52-Week Range$5.68 - $19.43

Previous CloseN/A

Volume73.34K

Average Volume (3M)1.32M

Market Cap

$1.09B

Enterprise Value$814.76M

Total Cash (Recent Filing)$351.88M

Total Debt (Recent Filing)$2.38M

Price to Earnings (P/E)―

Beta0.84

Next Earnings

Aug 06, 2026

EPS Estimate

-0.8

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.75

Shares Outstanding61,458,046

10 Day Avg. Volume1,548,542

30 Day Avg. Volume1,323,507

Financial Highlights & Ratios

PEG Ratio-0.14

Price to Book (P/B)1.50

Price to Sales (P/S)0.00

P/FCF Ratio-3.48

Enterprise Value/Market Cap0.74

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-10.31K

Enterprise Value/Ebitda-3.69

Forecast

1Y Price Target

$33.56

Price Target Upside122.81% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

EPS Forecast (FY)-3.04

Revenue Forecast (FY)$19.68M

Bulls Say, Bears Say

Bulls Say

Very Low LeverageCullinan's extremely low debt load is a durable financial strength: it lowers bankruptcy and interest-rate risk, preserves flexibility to fund R&D via non-debt means, and gives management time to advance clinical programs before needing urgent external borrowing.

Promising Clinical Readouts (CLN-978)Robust early efficacy and tolerability for CLN-978, with planned Phase 2a expansion, represents a structural advancement: success would materially de-risk the autoimmune franchise, enable partners or commercialization pathways, and create a multi-year development roadmap.

Diversified R&D StrategyA diversified pipeline and collaborative development model reduce program-level binary risk: multiple candidates across modalities and partnerships increase the chance that at least one program reaches commercialization, supporting longer-term sustainability of the biotech business model.

Bears Say

Sustained Cash BurnPersistent, large negative operating cash flow is a structural constraint: ongoing cash burn requires repeated financing or partnerships, risks diluting shareholders, and can force prioritization or delay of programs if capital markets or partner deals slow over the next several quarters.

Pre‑commercial Revenue ProfileMinimal current revenue means the company lacks recurring commercial cash flow; long‑term value hinges on clinical and regulatory success of pipeline assets, making business outcomes binary and revenue visibility low for multiple quarters to years.

Eroding Equity And Negative ReturnsA meaningful decline in shareholder equity and deep negative ROE signal cumulative losses that shrink the balance sheet buffer: this reduces financial headroom for unexpected costs, increases probability of future dilution, and weakens metrics used by potential partners or acquirers.

Cullinan Management News

Cullinan Therapeutics price target raised to $46 from $33 at Clear Street

Clear Street raised the firm’s price target on Cullinan Therapeutics (CGEM) to $46 from $33 and keeps a...

28d ago

CGEM

Cullinan Therapeutics reports CLN-978, velinotamig data

Cullinan Therapeutics (CGEM) reported clinical data and outlined global clinical development plans for CLN-978, a CD19xCD3 T cell...

28d ago

CGEM

Cullinan Therapeutics Shareholders Back Directors and Governance Measures

Cullinan Management ( ($CGEM) ) just unveiled an announcement. Cullinan Therapeutics held its Annual Meeting of Stockholders on...

22d ago

CGEM

Cullinan Therapeutics Highlights Positive Early Autoimmune Trial Data

Cullinan Management ( ($CGEM) ) has shared an announcement. On June 10, 2026, Cullinan Therapeutics reported updated Phase...

28d ago

CGEM

Buy Rating on Cullinan Reinforced by Encouraging Early CLN-978 Autoimmune Data and High Upside Potential

In a report released yesterday, Samantha Semenkow from Citi maintained a Buy rating on Cullinan Management, with a...

29d ago

CGEM

Cullinan Showcases Promising CLN-978 Phase 1 Autoimmune Data

An update from Cullinan Management ( ($CGEM) ) is now available. On June 6, 2026, Cullinan Therapeutics presented...

1M ago

CGEM

Cullinan Therapeutics Reiterated as Buy on Promising CLN-978 Data; $30 Price Target Maintained

Morgan Stanley analyst Sean Laaman maintained a Buy rating on Cullinan Management yesterday and set a price target...

1M ago

CGEM

Cullinan Therapeutics presents clinical data for CLN-978

Cullinan Therapeutics (CGEM) announced that it will present initial clinical data from two ongoing Phase 1 studies of...

1M ago

CGEM

Cullinan’s CLN-978 Lupus Study Opens a New Autoimmune Path for CGEM Investors

Cullinan Therapeutics Inc ($CGEM) announced an update on their ongoing clinical study. The Phase 1b study “A Phase...

1M ago

CGEM

Cullinan to host Immunology Day event, announce data for CLN-978, Velinotamig

Cullinan Therapeutics (CGEM) announced that the Company will host an in-person Immunology Day event in New York City...

1M ago

CGEM

Cullinan post-EULAR share pullback ‘unwarranted,’ says Clear Street

Clear Street reiterated a Buy rating and $33 price target on Cullinan Therapeutics (CGEM), saying the firm views...

2M ago

CGEM

Cullinan Therapeutics receives orphan drug designation for CLN-049

Cullinan Therapeutics (CGEM) announced that the FDA has granted orphan drug designation to CLN-049, a novel, investigational FLT3xCD3...

2M ago

CGEM

Cullinan Management Shares Promising Early CLN-978 Autoimmune Data

Cullinan Management ( ($CGEM) ) has shared an announcement. On May 18, 2026, Cullinan Therapeutics reported initial clinical...

2M ago

CGEM

Cullinan Therapeutics price target raised to $37 from $36 at Wedbush

Wedbush raised the firm’s price target on Cullinan Therapeutics (CGEM) to $37 from $36 and keeps an Outperform...

2M ago

CGEM

CGEM FAQ

What was Cullinan Therapeutics Inc’s price range in the past 12 months?

Cullinan Therapeutics Inc lowest stock price was $5.68 and its highest was $19.43 in the past 12 months.

What is Cullinan Therapeutics Inc’s market cap?

Cullinan Therapeutics Inc’s market cap is $1.09B.

When is Cullinan Therapeutics Inc’s upcoming earnings report date?

Cullinan Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 29 days.

How were Cullinan Therapeutics Inc’s earnings last quarter?

Cullinan Therapeutics Inc released its earnings results on May 07, 2026. The company reported -$0.75 earnings per share for the quarter, beating the consensus estimate of -$0.836 by $0.086.

Is Cullinan Therapeutics Inc overvalued?

According to Wall Street analysts Cullinan Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cullinan Therapeutics Inc pay dividends?

Cullinan Therapeutics Inc does not currently pay dividends.

What is Cullinan Therapeutics Inc’s EPS estimate?

Cullinan Therapeutics Inc’s EPS estimate is -0.8.

How many shares outstanding does Cullinan Therapeutics Inc have?

Cullinan Therapeutics Inc has 61,458,046 shares outstanding.

What happened to Cullinan Therapeutics Inc’s price movement after its last earnings report?

Cullinan Therapeutics Inc reported an EPS of -$0.75 in its last earnings report, beating expectations of -$0.836. Following the earnings report the stock price went down -1.801%.

Which hedge fund is a major shareholder of Cullinan Therapeutics Inc?

Currently, no hedge funds are holding shares in CGEM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Cullinan Management Stock Smart Score

Outperform

Fundamentals

Return on Equity

-51.45%

Trailing 12-Months

Asset Growth

-30.48%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cullinan Therapeutics Inc

Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.

Cullinan Management (CGEM) Earnings & Revenues

Historic Earnings Reports

CGEM Stock 12 Month Forecast

Average Price Target

$33.56

▲(122.81% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","26":"$26","47":"$47","15.5":"$15.5","36.5":"$36.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":46,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$46.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.55555555555556,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$33.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,15.5,26,36.5,47],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.28,19.48923076923077,21.69846153846154,23.907692307692308,26.11692307692308,28.326153846153847,30.535384615384615,32.744615384615386,34.95384615384616,37.16307692307692,39.37230769230769,41.58153846153846,43.79076923076923,{"y":46,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.28,18.53196581196581,19.783931623931625,21.035897435897436,22.28786324786325,23.53982905982906,24.79179487179487,26.043760683760684,27.2957264957265,28.54769230769231,29.79965811965812,31.051623931623933,32.30358974358974,{"y":33.55555555555556,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.28,17.79692307692308,18.313846153846153,18.83076923076923,19.34769230769231,19.864615384615384,20.38153846153846,20.89846153846154,21.415384615384617,21.932307692307692,22.44923076923077,22.966153846153844,23.483076923076922,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.64,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.67,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.49,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.66,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.75,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.71,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.99,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.94,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.43,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.21,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.28,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >